September 28, 2023: ASRI names Andrew N. Barynski, Ph.D. as Chief Operations Officer. Congratulations Dr. Bartynski!
June 13, 2023: In a pilot study designed to detect deuterated MDMA (MDMA-d3) in a test subject, ASRI scientists report the first observation of MDMA-d3 in human urine using enzyme-linked immunoassay (ELISA) and LC-MS/MS mass spectral analysis.
November 23, 2022: The first FDA-approved clinical trial to explore a low dose psilocybin pulse regimen for the suppression of cluster headache is conducted at Yale University. The psilocybin was synthesized and provided by ASRI scientists, who co-authored the manuscript.
October 14, 2022: ASRI Founder and President, Dr. Nicholas V. Cozzi, presents ASRI research at the Horizons New York 2022: Perspectives on Psychedelics Conference, New York City, October 12-16, 2022.
July 6, 2022: The Alexander Shulgin Research Institute and CaaMTech announce collaboration to study novel compounds from the Shulgin Vault. Shulgin compounds will be studied by X-ray diffraction crystallography at Dr. David Manke’s lab at UMass-Dartmouth.
June 3, 2022: The first FDA-approved clinical study of the safety, tolerability, and efficacy of N,N-dimethyltryptamine (DMT) in Major Depressive Disorder is co-authored by ASRI scientists, who synthesized the DMT hemifumarate employed in the study.
December 20, 2021: ASRI scientists help bring new clarity to psilocybin crystal polymorphs using X-ray diffraction crystallography.
December 9, 2021: ASRI raises $7.2 million in Seed financing round. Press release here.
April 19, 2021: The Alexander Shulgin Research Institute is incorporated by Ann Shulgin, Paul Daley, and Nicholas Cozzi. Happy Bicycle Day!
